Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 1 - 20 of about 573 ／ All the affair displays >>

Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer. Reviewed

Kanda M, Kasahara Y, Shimizu D, Shinozuka T, Sasahara M, Nakamura S, Iguchi Y, Katsuno M, Kodera Y, Obika S

British journal of cancer 2024.9

A nationwide survey on the safety of cricothyrotomy: a multicenter retrospective study in Japan Reviewed

Booka, E; Takeuchi, H; Kikuchi, H; Miura, A; Kanda, M; Kawaguchi, Y; Hamai, Y; Nasu, M; Sato, S; Inoue, M; Okubo, K; Ogawa, R; Sato, H; Yoshino, S; Takebayashi, K; Kono, K; Toh, Y; Katori, Y

ESOPHAGUS 2024.9

ASO Visual Abstract: Therapeutic Potential of Antibody Targeting Neuronal Pentraxin Receptor in Esophageal Squamous Cell Carcinoma Reviewed

Shinozuka, T; Kanda, M; Sato, Y; Shimizu, D; Umeda, S; Takami, H; Hattori, N; Hayashi, M; Tanaka, C; Kodera, Y

ANNALS OF SURGICAL ONCOLOGY Vol. 31 ( 9 ) page： 5776 - 5777 2024.9

Therapeutic Potential of Antibody Targeting Neuronal Pentraxin Receptor in Esophageal Squamous Cell Carcinoma. Reviewed International journal

Takahiro Shinozuka, Mitsuro Kanda, Yusuke Sato, Dai Shimizu, Shinichi Umeda, Hideki Takami, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Yasuhiro Kodera

Annals of surgical oncology Vol. 31 ( 9 ) page： 5674 - 5682 2024.9

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite advances in multidisciplinary treatments and immune checkpoint inhibitors. We previously reported that neural pentraxin receptor (NPTXR), a transmembrane protein mainly expressed in the brain and involved in synaptic transmission, is implicated in gastric cancer malignancy. This study evaluated the expression and function of NPTXR in ESCC, the therapeutic potential of monoclonal antibody (mAb) against NPTXR, and its prognostic value in ESCC patients. METHODS: The study involved analyzing the NPTXR expression in 21 ESCC cell lines and total 371 primary ESCC tissue samples using quantitative reverse-transcription polymerase chain reaction and immunohistochemistry. The impact of NPTXR on the malignant behavior of ESCC was examined using small interfering RNA-mediated knockdown and a subsequent assessment of cell proliferation, apoptosis, and adhesion. This study further investigated the efficacy of anti-NPTXR mAb in vitro and associations between the expression of NPTXR messenger RNA (mRNA) and protein with clinicopathological factors and the prognosis. RESULTS: NPTXR was overexpressed in several ESCC cell lines and primary ESCC tissues. Knockdown of NPTXR in ESCC cells resulted in reduced proliferation, increased apoptosis, and decreased cell adhesion. The mAb against NPTXR significantly inhibited ESCC cell proliferation in vitro. A high NPTXR expression in patient tissues was correlated with a worse overall survival, suggesting its potential as a prognostic biomarker. CONCLUSIONS: NPTXR influences the malignant behavior of ESCC cells. Anti-NPTXR mAb may be a promising therapeutic agent, and its expression in ESCC tissues may serve as a prognostic biomarker.

DOI： 10.1245/s10434-024-15353-2

Web of Science

PubMed

Preclinical toxicological assessment of amido-bridged nucleic acid-modified antisense oligonucleotides targeting synaptotagmin XIII for intra-abdominal treatment of peritoneal metastasis of gastric cancer Reviewed

Mitsuro Kanda, Nao Takano, Hiroshi Miyauchi, Kohei Ueda, Masaaki Mizuno, Yuuya Kasahara, Yasuhiro Kodera, Satoshi Obika

Gastric Cancer 2024.8

Language：English Publishing type：Research paper (scientific journal)

Background: Peritoneal metastasis of gastric cancer is closely associated with dismal prognosis. In previous preclinical proof-of-concept studies, an amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotide (ASO), designated ASO-4733 that targets the gene encoding synaptotagmin XIII (SYT13), inhibited cellular functions required for the formation of peritoneal metastasis of gastric cancer cells. ASO-4733 achieved therapeutic effects when intra-abdominally administered to mouse xenograft models. Here, we conducted an analysis of Syt13-deficient mice to determine the pharmacokinetics and toxicity of intra-abdominal administration of ASO-4733. Methods: The effects of Syt13-deficiency in mice were determined. Good Laboratory Practice toxicity tests and the toxicokinetics of intra-abdominal administration of ASO-4733 were conducted in cynomolgus monkeys and rats. The pharmacokinetics of ASO-4733 administered intravenously or intra-abdominally to rats were investigated. Results: Syt13-deficient mice exhibited normal reproduction, organ functions, and motor functions. Weekly intra-abdominal administration of ASO-4733 (125 mg/kg), corresponding to a 50-fold increase of the estimated clinical dose for 4 weeks, was well tolerated by cynomolgus monkeys. In rats, off-target toxicity (not attributable to hybridization) was observed after weekly intra-abdominal administration of ASO-4733. Blood concentrations of ASO-4733 were lower and rose more slowly after intra-abdominal administration compared with intravenous administration. Conclusions: The preclinical profile of intra-abdominal administration of ASO-4733 demonstrated its suitability for entry into clinical trials of patients with peritoneal metastasis of gastric cancer.

DOI： 10.1007/s10120-024-01548-9

Web of Science

Scopus

PubMed

Koki Nakanishi, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Dai Shimizu, Chie Tanaka, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2024.8

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Large type 3 (diameter ≥ 8 cm) and type 4 gastric cancers have been arbitrarily combined in Japan as a single entity. However, whether these two types are oncologically similar remain unclear. This study aimed to clarify this issue. METHODS: In this retrospective study, we analyzed a database of 3,575 patients from nine institutions who underwent gastrectomy between 2010 and 2014. Using propensity scores to balance significant variables, we compared prognoses and tumor recurrences. RESULTS: Of patients with clinical T3/T4 who underwent R0 resection, 75 and 73 had large type 3 and 4 tumors, respectively. Patients with type 4 tumors had significantly lower overall survival rates than those of patients with large type 3 tumors (hazard ratio [HR] 1.77; 95% confidence interval [CI] 1.14-2.74). However, among the large type 3 tumors, a remarkable difference in prognosis was observed between the differentiated and undifferentiated histological types. A comparison was made between large type 3 with undifferentiated phenotype and type 4, each with 39 patients after propensity score matching. Outcomes in both groups were similar in terms of overall survival (HR 1.28; 95% CI 0.73-2.25) and relapse-free survival (HR 1.34; 95% CI 0.80-2.27). No statistically significant differences were observed in the incidence of peritoneal recurrence (35.9% vs. 46.1%, P = 0.36) and lymph node recurrence (25.6% vs. 12.8%, P = 0.15). CONCLUSIONS: Large type 3 tumors with undifferentiated phenotype and type 4 tumors were oncologically similar. This subgroup could be considered as a new entity for future clinical trials.

DOI： 10.1007/s10120-024-01546-x

Web of Science

PubMed

ASO Author Reflections: Evaluating NPTXR as a Prognostic Biomarker and Therapeutic Target in Esophageal Squamous Cell Carcinoma Reviewed

Shinozuka, T; Kanda, M; Kodera, Y

ANNALS OF SURGICAL ONCOLOGY Vol. 31 ( 8 ) page： 5263 - 5272 2024.8

Exacerbated prognostic impact of multiple intramural metastasis versus single intramural metastasis of thoracic esophageal squamous cell carcinoma: evidence from an Uzbekistan cohort Reviewed

Yusupbekov, A; Shinozuka, T; Juraev, E; Usmanov, B; Kanda, M; Sakamoto, J; Tuychiev, O

SURGERY TODAY Vol. 54 ( 7 ) page： 771 - 778 2024.7

The long-term quality of life after distal and pylorus-preserving gastrectomy for stage I gastric cancer: A prospective multi-institutional study (CCOG1601). Reviewed

Chie Tanaka, Mitsuro Kanda, Kazunari Misawa, Yoshinari Mochizuki, Takuya Watanabe, Masashi Hattori, Kiyoshi Ishigure, Satoshi Sueoka, Hitoshi Teramoto, Akiharu Ishiyama, Ikue Nonogaki, Hidenobu Matsushita, Kenta Murotani, Yasuhiro Kodera

Surgery today 2024.6

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: While regarded as function-preserving gastrectomy, few prospective longitudinal clinical trials have addressed the postoperative quality of life (QOL) after pylorus-preserving gastrectomy (PPG). We prospectively compared chronological changes in postoperative body weight and the QOL between PPG and distal gastrectomy (DG) for pathological Stage I gastric cancer (GC). METHODS: We conducted a multi-institutional prospective study (CCOG1601) to evaluate patients who underwent DG and PPG. The QOL was examined using the European Organization for Research and Treatment of Cancer Quality of life questionnaire-C30 (EORTC QLQ-C30) and the Post-Gastrectomy Syndrome Assessment Scale-37 (PGSAS-37). A total of 295 patients were enrolled from 15 institutions, and propensity score matching was performed to adjust for the essential variables for comparison analyses. RESULTS: After propensity score matching, 25 pairs of patients were identified. In the first postoperative month, DG achieved a superior nausea and vomiting score (EORTC QLQ-C30) and meal-related distress, indigestion, and dumping scores (PGSAS-37). No significant differences were noted between DG and PPG in the long-term QOL. Postoperative body weight loss was similar in both groups. CONCLUSIONS: This prospective observational study failed to demonstrate the superiority of PPG over DG in terms of postoperative body weight changes and the QOL.

DOI： 10.1007/s00595-024-02881-3

Web of Science

PubMed

Prognostic Impact of <i>CDKN2A</i> Mutations Associated With Smoking and Drinking History in Japanese Digestive Cancers Reviewed

Fujita, K; Hayashi, M; Nakagawa, N; Kurimoto, K; Inokawa, Y; Takami, H; Nakanishi, K; Umeda, S; Shimizu, D; Hattori, N; Kanda, M; Tanaka, C; Nakayama, G; Kodera, Y

ANTICANCER RESEARCH Vol. 44 ( 6 ) page： 2699 - 2707 2024.6

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023 Reviewed

Kitagawa, Y; Matsuda, S; Gotoda, T; Kato, K; Wijnhoven, B; Lordick, F; Bhandari, P; Kawakubo, H; Kodera, Y; Terashima, M; Muro, K; Takeuchi, H; Mansfield, PF; Kurokawa, Y; So, J; Mönig, SP; Shitara, K; Rha, SY; Janjigian, Y; Takahari, D; Chau, I; Sharma, P; Ji, JF; de Manzoni, G; Nilsson, M; Kassab, P; Hofstetter, WL; Smyth, EC; Lorenzen, S; Doki, Y; Law, S; Oh, D; Ho, KY; Koike, T; Shen, L; van Hillegersberg, R; Kawakami, H; Xu, RH; Wainberg, Z; Yahagi, N; Lee, YY; Singh, R; Ryu, MH; Ishihara, R; Xiao, ZL; Kusano, C; Grabsch, HI; Hara, H; Mukaisho, KI; Makino, T; Kanda, M; Booka, E; Suzuki, S; Hatta, W; Kato, M; Maekawa, A; Kawazoe, A; Yamamoto, S; Nakayama, I; Narita, Y; Yang, HK; Yoshida, M; Sano, T

GASTRIC CANCER Vol. 27 ( 3 ) page： 401 - 425 2024.5

Outcomes of surgical treatment for enterovesical fistula in Crohn's disease. Reviewed

Hattori N, Nakayama G, Umeda S, Nakamura M, Yamamura T, Sawada T, Nakanishi K, Shimizu D, Kanda M, Hayashi M, Tanaka C, Kodera Y

Nagoya journal of medical science Vol. 86 ( 2 ) page： 280 - 291 2024.5

Killer cell lectin-like receptor G2 facilitates aggressive phenotypes of gastric cancer cells via dual activation of the ERK1/2 and JAK/STAT pathways Reviewed

Ito, Y; Kanda, M; Sasahara, M; Tanaka, C; Shimizu, D; Umeda, S; Inokawa, Y; Hattori, N; Hayashi, M; Nakayama, G; Kodera, Y

GASTRIC CANCER Vol. 27 ( 3 ) page： 506 - 518 2024.5

Long-term quality of life after open and laparoscopic total gastrectomy for stage I gastric cancer: A prospective multi-institutional study (CCOG1504) Reviewed

Tanaka, C; Kanda, M; Misawa, K; Mochizuki, Y; Hattori, M; Sueoka, S; Watanabe, T; Yamada, T; Murotani, K; Kodera, Y

ANNALS OF GASTROENTEROLOGICAL SURGERY 2024.4

Therapeutic antibody targeting natriuretic peptide receptor 1 inhibits gastric cancer growth <i>via</i> BCL-2-mediated intrinsic apoptosis Reviewed

Sasahara, M; Kanda, M; Tanaka, C; Shimizu, D; Umeda, S; Takami, H; Inokawa, Y; Hattori, N; Hayashi, M; Nakayama, G; Kodera, Y

INTERNATIONAL JOURNAL OF CANCER Vol. 154 ( 7 ) page： 1272 - 1284 2024.4

Risk Factors for Long-term Body Weight Loss After Proximal Gastrectomy: A Retrospective Analysis. Reviewed International journal

Yuya Agatsuma, Koki Nakanishi, Chie Tanaka, Mitsuro Kanda, Dai Shimizu, Shinichi Umeda, Keisuke Kurimoto, Yoshikuni Inokawa, Hideki Takami, Norifumi Hattori, Masamichi Hayashi, Goro Nakayama, Michitaka Fujiwara, Yasuhiro Kodera

Anticancer research Vol. 44 ( 4 ) page： 1645 - 1651 2024.4

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND/AIM: Proximal gastrectomy (PG) is a therapy for early-stage proximal gastric cancer and offers advantages such as the preservation of food storage capacity and less body weight loss (BWL). Nevertheless, significant BWL following PG may occur, affecting the patient's well-being and survival. In this study, we aimed to identify the relevant factors for BWL following PG by analyzing an institutional database of patients. PATIENTS AND METHODS: We enrolled 58 consecutive patients who underwent PG for gastric or esophagogastric junction cancer at our institution between April 2004 and March 2021. Based on BWL at 12 months postoperatively, we retrospectively compared and examined patient characteristics, surgical details, and nutritional markers. RESULTS: The mean BWL of the 58 patients included in this analysis was 14.0±7.2%. When the patients were divided into BWL-moderate (n=29) and BWL-severe (n=29) groups using a cutoff value of 15.7%, the latter experienced early BWL within 1 month postoperatively, primarily due to body fat mass reduction, with no recovery during the 60 months of follow up. In contrast, gradual recovery was observed among patients in the BWL-moderate group after experiencing the lowest body weight 24 months postoperatively. A greater decrease in body fat mass than in muscle mass was observed in both groups. Blood hemoglobin levels did not recover in the BWL-severe group. CONCLUSION: The BWL-severe group after proximal gastrectomy demonstrated significantly greater early postoperative BWL, primarily attributed to a reduction in body fat mass, with hardly any recovery. Early postoperative nutritional intervention might be proposed to prevent long-term BWL.

DOI： 10.21873/anticanres.16963

Web of Science

PubMed

希少癌に対する治療戦略-標準化に向けた取り組み- 十二指腸癌に対する膵頭十二指腸切除術施行症例のNCDデータベースを用いた観察研究リンパ節郭清範囲,周術期化学療法,解剖学的部位別リンパ節転移率の分析 Reviewed

林真路, 高見秀樹, 猪川祥邦, 田中晴祥, 栗本景介, 中川暢彦, 山本博之, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 山上裕機, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 124回 page： WS - 1 2024.4

A multi-institutional prospective observational study to compare postoperative quality of life of patients who undergo total or proximal gastrectomy for early gastric cancer (CCOG1602). Reviewed International journal

Mitsuro Kanda, Chie Tanaka, Kazunari Misawa, Yoshinari Mochizuki, Takuya Watanabe, Satoshi Sueoka, Akiharu Ishiyama, Takanobu Yamada, Takashi Oshima, Masashi Hattori, Shinya Koike, Kiyoshi Ishigure, Hitoshi Teramoto, Kenta Murotani, Yasuhiro Kodera

World journal of surgery Vol. 48 ( 3 ) page： 681 - 691 2024.3

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Proximal gastrectomy (PG) has become an increasingly preferred procedure for treating early cancer in the upper third of the stomach. However, advantages of PG in postoperative quality of life (QOL) over total gastrectomy (TG) has not fully proven. METHODS: We conducted a multi-institutional prospective observational study (CCOG1602) of patients who undergo TG or PG for cStage I gastric cancer. We used the PGSAS-37 and EORTC-QLQ-C30 to evaluate the changes in body weight and QOL over a 3-year postoperative period. The primary endpoint was the weight loss rate 3 years after surgery. RESULTS: We enrolled 109 patients from 18 institutions and selected 65 and 19 patients for inclusion in the TG and PG groups, respectively. Mean postoperative weight loss rates were 16.0% and 11.7% for the TG and PG groups, respectively (p = 0.056, Cohen's d 0.656) during postoperative year 1% and 15.0% and 10.8% for TG and PG (p = 0.068, Cohen's d 0.543), respectively, during postoperative year 3, indicating that the PG group achieved a better trend with a moderate effect size. According to the PGSAS-37, the PG group experienced a better trend in the indigestion subscale (p < 0.001, Cohen's d -1.085) and total symptom score (p = 0.050, Cohen's d -0.59) during postoperative year 3 compared with the TG group. In contrast, the EORTC-QLQ-C30 detected no difference between the groups at any time point during 3-year postoperative period. CONCLUSIONS: This prospective study demonstrates that PG tended to be more favorable compared with TG with respect to postoperative weight loss and QOL, particularly regarding indigestion.

DOI： 10.1002/wjs.12088

Web of Science

PubMed

ASO Visual Abstract: Absence of Hypercoagulation Status After Neoadjuvant Treatment is Associated with Favorable Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma Reviewed

Sugiyama, F; Kanda, M; Shimizu, D; Umeda, S; Inokawa, Y; Hattori, N; Hayashi, M; Tanaka, C; Nakayama, G; Kodera, Y

ANNALS OF SURGICAL ONCOLOGY 2024.2

胃癌診療におけるバイオマーカーの意義胃癌転移形式特異的バイオマーカーの同定と創薬への展開 Reviewed

神田光郎, 田中千恵, 清水大, 中西香企, 梅田晋一, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 中山吾郎, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 96回 page： 162 - 162 2024.2

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro